X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (95) 95
humans (95) 95
index medicus (89) 89
oncology (72) 72
middle aged (57) 57
cancer (51) 51
aged (49) 49
obstetrics & gynecology (48) 48
adult (46) 46
obstetrics and gynecology (37) 37
ovarian cancer (35) 35
chemotherapy (32) 32
surgery (28) 28
carcinoma (27) 27
article (25) 25
cell line, tumor (25) 25
endometrial cancer (23) 23
laparoscopy (23) 23
animals (22) 22
ovarian neoplasms - pathology (22) 22
retrospective studies (21) 21
hematology, oncology and palliative medicine (20) 20
tumors (20) 20
ovarian neoplasms - drug therapy (19) 19
mice (18) 18
mutation (17) 17
aged, 80 and over (16) 16
expression (16) 16
care and treatment (14) 14
diagnosis (13) 13
flow cytometry (13) 13
immunotherapy (13) 13
neoplasm staging (13) 13
ovarian neoplasms - metabolism (13) 13
paclitaxel (13) 13
robotics (13) 13
uterine neoplasms - drug therapy (13) 13
xenograft model antitumor assays (13) 13
abridged index medicus (12) 12
cervical cancer (12) 12
laparoscopic surgery (12) 12
ovarian neoplasms - genetics (12) 12
research (12) 12
uterine neoplasms - genetics (12) 12
women (12) 12
health aspects (11) 11
prognosis (11) 11
survival (11) 11
treatment outcome (11) 11
uterine neoplasms - pathology (11) 11
uterine serous carcinoma (11) 11
analysis (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
gene expression (10) 10
therapy (10) 10
trastuzumab (10) 10
breast-cancer (9) 9
cystadenocarcinoma, serous - drug therapy (9) 9
her2 (9) 9
hysterectomy (9) 9
immunohistochemistry (9) 9
in-vitro (9) 9
laparoscopy - methods (9) 9
antineoplastic agents - pharmacology (8) 8
carcinoma, ovarian epithelial (8) 8
cell adhesion molecules - immunology (8) 8
cisplatin (8) 8
disease-free survival (8) 8
drug resistance, neoplasm (8) 8
endometrial carcinoma (8) 8
endometrial neoplasms - pathology (8) 8
medical colleges (8) 8
pregnancy (8) 8
receptor, erbb-2 - genetics (8) 8
resistance (8) 8
uterine cervical neoplasms - pathology (8) 8
antibodies (7) 7
antigens, neoplasm - immunology (7) 7
cell proliferation - drug effects (7) 7
cell survival - drug effects (7) 7
epcam (7) 7
gene amplification (7) 7
genetic aspects (7) 7
gynecology (7) 7
hysterectomy - methods (7) 7
neoplasms, glandular and epithelial - drug therapy (7) 7
ovarian carcinoma (7) 7
ovarian neoplasms - immunology (7) 7
paclitaxel - administration & dosage (7) 7
receptor, erbb-2 - antagonists & inhibitors (7) 7
risk factors (7) 7
survival rate (7) 7
usage (7) 7
adenocarcinoma (6) 6
antimitotic agents (6) 6
antineoplastic agents (6) 6
carboplatin (6) 6
cystadenocarcinoma, serous - genetics (6) 6
cystadenocarcinoma, serous - pathology (6) 6
cytotoxicity (6) 6
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Obstetrics & Gynecology, ISSN 0029-7844, 05/2014, Volume 123 Suppl 1, pp. 116S - 117S
INTRODUCTION:Our goal was to evaluate whether didactics and simulation would help residents gain and retain knowledge of electrosurgery principles in an... 
Journal Article
2015, Cambridge Medicine, ISBN 9781139794671
Web Resource
2015, Cambridge Medicine, ISBN 9781139794671
Web Resource
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 2/2013, Volume 110, Issue 8, pp. 2916 - 2921
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 10/2016, Volume 113, Issue 43, pp. 12238 - 12243
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. e17128 - e17128
Journal Article
The Lancet Oncology, ISSN 1470-2045, 05/2019, Volume 20, Issue 5, pp. 636 - 648
Late-line treatment options for patients with ovarian cancer are few, with the proportion of patients achieving an overall response typically less than 10%,... 
BRCA MUTATION | SURVIVAL | POLY(ADP-RIBOSE) POLYMERASE | ONCOLOGY | RECURRENT EPITHELIAL OVARIAN | INHIBITOR | TUMORS | MAINTENANCE THERAPY | CHEMOTHERAPY | Care and treatment | Analysis | Ovarian cancer | Cancer
Journal Article
The Journal of Minimally Invasive Gynecology, ISSN 1553-4650, 11/2019, Volume 26, Issue 7, pp. 1389 - 1395
Radical trachelectomy is considered in patients with early-stage cervical cancer who desire future fertility. This article is accompanied by a video that... 
Fertility sparing | Trachelectomy | Robotic | Surgery | Gynecology | Laparoscopy | Uterine artery | SERIES | VAGINAL TRACHELECTOMY | FERTILITY | OBSTETRICS & GYNECOLOGY | PRESERVATION | WOMEN | STAGE CERVICAL-CANCER | PREGNANCY OUTCOMES | BILATERAL PELVIC LYMPHADENECTOMY | Squamous cell carcinoma | Analysis | Cervical cancer
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2015, Volume 139, Issue 3, pp. 601 - 601
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2015, Volume 139, Issue 3, pp. 592 - 592
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2017, Volume 23, Issue 19, pp. 5836 - 5845
Purpose: Carcinosarcomas (CS) are highly aggressive gynecologic malignancies containing both carcinomatous and sarcomatous elements with heterogeneous HER2/neu... 
EPITHELIAL-MESENCHYMAL TRANSITION | TRASTUZUMAB PLUS DOCETAXEL | PHASE-II TRIAL | GYNECOLOGIC-ONCOLOGY-GROUP | ONCOLOGY | GASTRIC-CANCER | SEROUS CARCINOMA | METASTATIC BREAST-CANCER | ENDOMETRIAL CARCINOSARCOMA | PRECLINICAL PROFILE | MONOCLONAL-ANTIBODY | Receptor, ErbB-2 - genetics | Uterine Neoplasms - pathology | Humans | Ovarian Neoplasms - pathology | Antibody-Dependent Cell Cytotoxicity - immunology | Pyrrolidinones - immunology | Immunoconjugates - administration & dosage | Indoles - administration & dosage | Carcinosarcoma - immunology | Immunoconjugates - immunology | Ovarian Neoplasms - genetics | Pyrrolidinones - administration & dosage | Female | Receptor, ErbB-2 - antagonists & inhibitors | Receptor, ErbB-2 - immunology | Gene Expression Regulation, Neoplastic - drug effects | Ovarian Neoplasms - drug therapy | Carcinosarcoma - pathology | Uterine Neoplasms - genetics | Maytansine - analogs & derivatives | Indoles - immunology | Trastuzumab - administration & dosage | Xenograft Model Antitumor Assays | Maytansine - administration & dosage | Animals | Uterine Neoplasms - drug therapy | Cell Line, Tumor | Carcinosarcoma - drug therapy | Carcinosarcoma - genetics | Cell Proliferation - drug effects | Mice | Trastuzumab - immunology | Maytansine - immunology | Uterine Neoplasms - immunology | Ovarian Neoplasms - immunology | Biotechnology | Animal models | Toxicity | Tumor cells | Effector cells | Cytotoxicity | Gene expression | ErbB-2 protein | Anticancer properties | Gene amplification | Chemotherapy | Uterus | Experimental design | Cell lines | Xenografts | Antitumor activity | Biocompatibility | In vivo methods and tests | Viability | Trastuzumab | Cancer | SYD985 | T-DM1 | HER2 | Uterine Carcinosarcoma | Ovarian Carcinosarcoma
Journal Article
British Journal of Cancer, ISSN 0007-0920, 09/2015, Volume 113, Issue 7, pp. 1020 - 1026
Journal Article
Journal Article
The Journal of Minimally Invasive Gynecology, ISSN 1553-4650, 01/2019, Volume 26, Issue 1, pp. 36 - 37
To present a surgical video in which bilateral uterine vasculature was ligated laparoscopically in order to preserve the uterus in a patient with postabortal... 
Ligation of the uterine artery | Laparoscopy | Fertility sparing | Obstetrics | Postabortal hemorrhage | OBSTETRICS & GYNECOLOGY
Journal Article
Journal of Surgical Oncology, ISSN 0022-4790, 02/2013, Volume 107, Issue 2, pp. 195 - 200
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 02/2017, Volume 16, Issue 2, pp. 323 - 333
Ovarian cancer is the most lethal gynecologic cancer. Claudin-3 and -4, the receptors for Clostridium perfringens enterotoxin (CPE), are overexpressed in more... 
CLAUDIN-4 | DIAGNOSIS | EFFICIENT TRANSFECTION | THERAPY | ONCOLOGY | CLOSTRIDIUM-PERFRINGENS ENTEROTOXIN | TERMINAL FRAGMENT | MICE | POLYMER LIBRARY | EXPRESSION | CARCINOMA | Genetic Therapy | Nanoparticles - chemistry | Humans | Ovarian Neoplasms - pathology | Cell Survival - genetics | Drug Resistance, Neoplasm | Drug Carriers | Drug Delivery Systems | Ovarian Neoplasms - genetics | Female | Tumor Burden - genetics | Antineoplastic Agents - pharmacology | Ovarian Neoplasms - metabolism | Disease Models, Animal | Cell Survival - drug effects | Gene Transfer Techniques | Promoter Regions, Genetic | Gene Expression | Genes, Transgenic, Suicide | Enterotoxins | Nanoparticles - ultrastructure | Xenograft Model Antitumor Assays | Animals | Tumor Burden - drug effects | Cell Line, Tumor | Ovarian Neoplasms - therapy | Mice | Nanoparticles - administration & dosage | Encapsulation | Flow cytometry | Ovarian carcinoma | Transcription | Toxicity | Cytotoxicity | Suicide | Ovarian cancer | Polylactide-co-glycolide | Nanoparticles | Receptors | Transfection | Xenografts | Biocompatibility | Diphtheria toxin | Suicide genes | Cytomegalovirus | Tumor cells | Tumor cell lines | Diphtheria | Cytometry | Chemotherapy | Cell death | In vivo methods and tests | Gene therapy | Immunofluorescence | Tumors | Cancer | Ovarian Cancer | Claudin-3 and -4 | Chemotherapy resistance | PLGA nanoparticles | Clostridium Perfringens Enterotoxin (CPE)
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 01/2019, Volume 116, Issue 2, pp. 619 - 624
Ovarian cancer remains the most lethal gynecologic malignancy. We analyzed the mutational landscape of 64 primary, 41 metastatic, and 17 recurrent fresh-frozen... 
Ovarian carcinoma | Whole-exome sequencing | BET inhibitors | Bilateral ovarian tumors | PIK3CA | COPY-NUMBER | MULTIDISCIPLINARY SCIENCES | ovarian carcinoma | whole-exome sequencing | bilateral ovarian tumors | Class I Phosphatidylinositol 3-Kinases - genetics | Class I Phosphatidylinositol 3-Kinases - metabolism | Humans | Neoplasm Recurrence, Local - drug therapy | Tumor Suppressor Protein p53 - genetics | Neoplasm Metastasis | BRCA1 Protein - metabolism | Female | Antineoplastic Agents - pharmacology | Ovarian Neoplasms | Neoplasm Recurrence, Local - metabolism | Tumor Suppressor Protein p53 - metabolism | Proto-Oncogene Proteins c-myc - metabolism | Azepines - pharmacology | Proteins - genetics | Triazoles - pharmacology | Xenograft Model Antitumor Assays | BRCA1 Protein - genetics | Animals | BRCA2 Protein - metabolism | Proteins - metabolism | Cell Line, Tumor | Neoplasm Recurrence, Local - genetics | Mice | Proto-Oncogene Proteins c-myc - genetics | Mutation | Proteins - antagonists & inhibitors | BRCA2 Protein - genetics | Relapse | Genetic aspects | Metastasis | Health aspects | Mutation (Biology) | Ovarian cancer | Cancer | p53 Protein | Genes | Xenotransplantation | c-Myc protein | Malignancy | Myc protein | Metastases | Gene sequencing | Xenografts | Evolution | Deoxyribonucleic acid--DNA | Nucleotide sequence | BRCA1 protein | Therapeutic applications | Gynecology | Breast cancer | Patients | Amplification | Chemotherapy | Inhibitors | Cell lines | Gain | DNA sequencing | Tumors | Biological Sciences
Journal Article
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, ISSN 0027-8424, 11/2019, Volume 116, Issue 45, pp. 22730 - 22736
Journal Article